International Journal of Thyroidology

Table. 6. Table 6

Clinical outcomes of CEA-negative patients at detection of recurrence

Age	Sex	T stage	Size (cm)	mLN (Number)	N stage	Metastasis (site)	Calcitonin (pg/mL)	CEA (ng/mL)	Clinical outcome
Patients with local recurrence
30	F	3a	4.0	10	1b	LN	185	1.3	Recur^a
50	M	1a	1.6	2	1a	LN	399	2.4	Death
58	M	1b	1.4	3	1a	LN	312	0.5	Recur
49	F	3b	1.5	11	1b	LN	162	0.5	Recur
52	M	1b	0.9	2	1b	LN	66	2.8	Recur^b
47	F	2	2.6	3	1a	LN	51	1.2	Death^c
51	M	1a	1.0	3	1a	LN	131	2.0	Recur
21	M	1a	0.6	7	1a	LN	159	3.0	Recur
37	F	1b	1.5	24	1b	LN	549	0.7	Recur
57	F	1a	1.2	1	1a	LN	78	2.4	Recur
42	F	3a	5.6	14	1b	LN	4542	4.2	Recur
Patients with distant recurrence
30	F	3a	4.0	10	1b	Lung	401	3.4	Recur^a
52	M	1a	0.9	2	1b	Lung	770	3.8	Recur^b
47	F	2	2.6	3	1a	Bone	3320	1.1	Death^c
72	M	3a	6.5	46	1b	Liver	14826	3.6	Death

CEA: carcinoembryonic antigen, LN: lymph node, mLN: metastatic lymph node

^a,b,cResults observed for the clinical course of the same patient are indicated by the same letter.